News | May 11, 2026
Bajaj Healthcare FY26 revenue rises 12.6% to Rs 6,110 million
Strong export-led growth and improved profitability as the company focuses on CNS drug development and global regulatory footprint
Strong export-led growth and improved profitability as the company focuses on CNS drug development and global regulatory footprint
Through strong industry cooperation, significant investment, and smart policy backing, API manufacturing may become self-reliant
Revenue from operations also dropped 8.3 per cent at Rs. 133.5 crore in Q3 FY25
EBITDA for the quarter is Rs. 21.6 crore as against Rs. 18.1 crore in Q2 FY24
Rusan’s API facility in Ankleshwar is GMP approved by other stringent international agencies as well
Plant is part of the company's CAD $30 million capital investment in the site
EUROAPI listing on Euronext Paris will occur in H1 2022, despite volatile market conditions
ICICI Securities expects Hemmo to grow its revenue at a CAGR of 30.0% over FY21E-FY23E
This acquisition marks PPS’ foray into the development and manufacturing of peptide APIs
Subscribe To Our Newsletter & Stay Updated
